The malaria treatment market size has grown steadily in recent years. It will grow from $1.55 billion in 2024 to $1.62 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to the discovery of effective drugs, vector control efforts, global health initiatives, scientific research, and health infrastructure development.
The malaria treatment market size is expected to see strong growth in the next few years. It will grow to $2.07 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to drug resistance monitoring, climate change impact, precision medicine and genomic approaches, healthcare financing reforms, and integration of digital health solutions. Major trends in the forecast period include epidemiological surveillance enhancement, alternative medicine integration, malaria vaccine development, data-driven treatment programs, and education and training programs.
The rising incidence of malaria is anticipated to drive the growth of the malaria treatment market in the future. Malaria is a potentially life-threatening disease transmitted by mosquitoes and caused by the Plasmodium parasite, characterized by recurring fevers and flu-like symptoms. Factors such as poverty, limited access to healthcare, climate change, insufficient malaria control measures, and drug resistance have contributed to this increase. Effective malaria treatment is essential for managing and curing infections caused by the Plasmodium parasite. For instance, the World Malaria Report 2023 published by the World Health Organization, a Switzerland-based intergovernmental organization, indicated that global malaria cases reached 249 million in 2022, an increase of five million compared to 2021. Therefore, the high incidence of malaria is driving the growth of the malaria treatment market.
The rise in healthcare spending is projected to fuel the growth of the malaria treatment market in the coming years. Healthcare spending refers to the total financial resources allocated to the healthcare sector in a specific region, country, or organization. Investment in malaria treatment is essential for effectively managing the disease and preventing its spread, ensuring timely access to diagnosis, antimalarial medications, and preventive measures. For example, in July 2024, the American Medical Association, a US-based professional association and lobbying group for physicians and medical students, reported that health spending in the United States increased by 4.1% in 2022, reaching $4.5 trillion or $13,493 per capita. Therefore, the increase in healthcare spending is driving the growth of the malaria treatment market.
Key players in the malaria treatment market are advancing technologies like the VERV Program to improve the efficiency and effectiveness of malaria diagnostics and treatments, with the goal of alleviating the disease burden in endemic regions. The VERV Program is an initiative from the Environmental Protection Agency (EPA) aimed at fostering the development of new mosquito control products to combat diseases such as malaria by providing expedited review vouchers for product registration. For example, in December 2023, the EPA, a US government agency, launched the Vector Expedited Review Voucher (VERV) Program. This program is designed to offer financial incentives to companies that create new pesticides specifically aimed at mosquito populations that have developed resistance to traditional insecticides. It will also streamline the registration process for eligible products, accelerating their availability in the market.
Leading companies in the malaria treatment market are prioritizing the development of vaccine rollouts to bolster prevention efforts and alleviate the global burden of malaria. A vaccine rollout involves the large-scale distribution and administration of vaccines to a population. For example, in July 2024, Gavi, a vaccine alliance based in Sweden, initiated the rollout of the R21 malaria vaccine. This vaccine is anticipated to significantly lower the incidence of malaria cases among children under five years old. The R21 malaria vaccine marks a crucial advancement in public health initiatives aimed at fighting malaria in children, with the expectation that it will lead to a notable decrease in both the disease burden and mortality rates associated with this preventable illness.
In November 2022, Novartis AG, a Switzerland-based pharmaceutical and healthcare company, joined forces with Medicines for Malaria Venture to conduct phase III clinical trials for a novel ganaplacide and lumefantrine-SDF medication combination targeting malaria in both adults and children. Medicines for Malaria Venture (MMV), as a Switzerland-based non-profit organization focused on antimalarial drug research and development, underscores the collaborative efforts within the industry to advance malaria treatment solutions.
Major companies operating in the malaria treatment market include Pfizer Inc., Merck & Co., Johnson & Johnson, Roche Holding AG, Bayer AG, Novartis AG, Sanofi SA, AstraZeneca Plc, GlaxoSmithKline PLC., Takeda Pharmaceutical Company Limited, Sumitomo Chemical Co. Ltd., Viatris Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Serum Institute of India, Cipla Ltd., Amneal Pharmaceuticals LLC, Lupin Ltd., Zydus Lifesciences Limited, Ipca Laboratories Ltd., Chongqing Holley Pharmaceutical Co. Ltd., Zydus Lifesciences Ltd., Medicines Sans Frontières, Strides Pharma Science Limited, Swiss Tropical and Public Health Institute (Swiss TPH), AdvaCare Pharma USA LLC, Medicines for Malaria Venture (MMV), VLP Therapeutics LLC, Actiza Pharmaceutical Private Limited.
Middle East and Africa was the largest region in the malaria treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malaria treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the malaria treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Malaria treatment encompasses the medical interventions and procedures aimed at diagnosing, managing, and curing malaria, a potentially life-threatening mosquito-borne disease caused by the Plasmodium parasite.
The primary components of malaria treatment include prescription medications, vaccines, diagnostic tests, and other therapeutic approaches. Prescription medications are pharmaceuticals that require a valid prescription from a healthcare professional. In the context of malaria treatment, these drugs are essential for providing targeted and regulated therapy to combat the infection. They can be administered through oral, parenteral, and intravenous routes and are distributed through various channels such as direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. These channels serve hospitals, specialty clinics, home care settings, and other end users, ensuring a comprehensive reach for malaria treatment options.
The malaria treatment market research report is one of a series of new reports that provides malaria treatment market statistics, including malaria treatment industry global market size, regional shares, competitors with a malaria treatment market share, detailed malaria treatment market segments, market trends and opportunities, and any further data you may need to thrive in the malaria treatment industry. This malaria treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The malaria treatment market consists of sales of antimicrobial medications, antimalarial drugs, antipyretics, intravenous fluids, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The malaria treatment market size is expected to see strong growth in the next few years. It will grow to $2.07 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to drug resistance monitoring, climate change impact, precision medicine and genomic approaches, healthcare financing reforms, and integration of digital health solutions. Major trends in the forecast period include epidemiological surveillance enhancement, alternative medicine integration, malaria vaccine development, data-driven treatment programs, and education and training programs.
The rising incidence of malaria is anticipated to drive the growth of the malaria treatment market in the future. Malaria is a potentially life-threatening disease transmitted by mosquitoes and caused by the Plasmodium parasite, characterized by recurring fevers and flu-like symptoms. Factors such as poverty, limited access to healthcare, climate change, insufficient malaria control measures, and drug resistance have contributed to this increase. Effective malaria treatment is essential for managing and curing infections caused by the Plasmodium parasite. For instance, the World Malaria Report 2023 published by the World Health Organization, a Switzerland-based intergovernmental organization, indicated that global malaria cases reached 249 million in 2022, an increase of five million compared to 2021. Therefore, the high incidence of malaria is driving the growth of the malaria treatment market.
The rise in healthcare spending is projected to fuel the growth of the malaria treatment market in the coming years. Healthcare spending refers to the total financial resources allocated to the healthcare sector in a specific region, country, or organization. Investment in malaria treatment is essential for effectively managing the disease and preventing its spread, ensuring timely access to diagnosis, antimalarial medications, and preventive measures. For example, in July 2024, the American Medical Association, a US-based professional association and lobbying group for physicians and medical students, reported that health spending in the United States increased by 4.1% in 2022, reaching $4.5 trillion or $13,493 per capita. Therefore, the increase in healthcare spending is driving the growth of the malaria treatment market.
Key players in the malaria treatment market are advancing technologies like the VERV Program to improve the efficiency and effectiveness of malaria diagnostics and treatments, with the goal of alleviating the disease burden in endemic regions. The VERV Program is an initiative from the Environmental Protection Agency (EPA) aimed at fostering the development of new mosquito control products to combat diseases such as malaria by providing expedited review vouchers for product registration. For example, in December 2023, the EPA, a US government agency, launched the Vector Expedited Review Voucher (VERV) Program. This program is designed to offer financial incentives to companies that create new pesticides specifically aimed at mosquito populations that have developed resistance to traditional insecticides. It will also streamline the registration process for eligible products, accelerating their availability in the market.
Leading companies in the malaria treatment market are prioritizing the development of vaccine rollouts to bolster prevention efforts and alleviate the global burden of malaria. A vaccine rollout involves the large-scale distribution and administration of vaccines to a population. For example, in July 2024, Gavi, a vaccine alliance based in Sweden, initiated the rollout of the R21 malaria vaccine. This vaccine is anticipated to significantly lower the incidence of malaria cases among children under five years old. The R21 malaria vaccine marks a crucial advancement in public health initiatives aimed at fighting malaria in children, with the expectation that it will lead to a notable decrease in both the disease burden and mortality rates associated with this preventable illness.
In November 2022, Novartis AG, a Switzerland-based pharmaceutical and healthcare company, joined forces with Medicines for Malaria Venture to conduct phase III clinical trials for a novel ganaplacide and lumefantrine-SDF medication combination targeting malaria in both adults and children. Medicines for Malaria Venture (MMV), as a Switzerland-based non-profit organization focused on antimalarial drug research and development, underscores the collaborative efforts within the industry to advance malaria treatment solutions.
Major companies operating in the malaria treatment market include Pfizer Inc., Merck & Co., Johnson & Johnson, Roche Holding AG, Bayer AG, Novartis AG, Sanofi SA, AstraZeneca Plc, GlaxoSmithKline PLC., Takeda Pharmaceutical Company Limited, Sumitomo Chemical Co. Ltd., Viatris Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Serum Institute of India, Cipla Ltd., Amneal Pharmaceuticals LLC, Lupin Ltd., Zydus Lifesciences Limited, Ipca Laboratories Ltd., Chongqing Holley Pharmaceutical Co. Ltd., Zydus Lifesciences Ltd., Medicines Sans Frontières, Strides Pharma Science Limited, Swiss Tropical and Public Health Institute (Swiss TPH), AdvaCare Pharma USA LLC, Medicines for Malaria Venture (MMV), VLP Therapeutics LLC, Actiza Pharmaceutical Private Limited.
Middle East and Africa was the largest region in the malaria treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malaria treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the malaria treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Malaria treatment encompasses the medical interventions and procedures aimed at diagnosing, managing, and curing malaria, a potentially life-threatening mosquito-borne disease caused by the Plasmodium parasite.
The primary components of malaria treatment include prescription medications, vaccines, diagnostic tests, and other therapeutic approaches. Prescription medications are pharmaceuticals that require a valid prescription from a healthcare professional. In the context of malaria treatment, these drugs are essential for providing targeted and regulated therapy to combat the infection. They can be administered through oral, parenteral, and intravenous routes and are distributed through various channels such as direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. These channels serve hospitals, specialty clinics, home care settings, and other end users, ensuring a comprehensive reach for malaria treatment options.
The malaria treatment market research report is one of a series of new reports that provides malaria treatment market statistics, including malaria treatment industry global market size, regional shares, competitors with a malaria treatment market share, detailed malaria treatment market segments, market trends and opportunities, and any further data you may need to thrive in the malaria treatment industry. This malaria treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The malaria treatment market consists of sales of antimicrobial medications, antimalarial drugs, antipyretics, intravenous fluids, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Malaria Treatment Market Characteristics3. Malaria Treatment Market Trends and Strategies4. Malaria Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Malaria Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Malaria Treatment Market34. Recent Developments in the Malaria Treatment Market
5. Global Malaria Treatment Growth Analysis and Strategic Analysis Framework
6. Malaria Treatment Market Segmentation
7. Malaria Treatment Market Regional and Country Analysis
8. Asia-Pacific Malaria Treatment Market
9. China Malaria Treatment Market
10. India Malaria Treatment Market
11. Japan Malaria Treatment Market
12. Australia Malaria Treatment Market
13. Indonesia Malaria Treatment Market
14. South Korea Malaria Treatment Market
15. Western Europe Malaria Treatment Market
16. UK Malaria Treatment Market
17. Germany Malaria Treatment Market
18. France Malaria Treatment Market
19. Italy Malaria Treatment Market
20. Spain Malaria Treatment Market
21. Eastern Europe Malaria Treatment Market
22. Russia Malaria Treatment Market
23. North America Malaria Treatment Market
24. USA Malaria Treatment Market
25. Canada Malaria Treatment Market
26. South America Malaria Treatment Market
27. Brazil Malaria Treatment Market
28. Middle East Malaria Treatment Market
29. Africa Malaria Treatment Market
30. Malaria Treatment Market Competitive Landscape and Company Profiles
31. Malaria Treatment Market Other Major and Innovative Companies
35. Malaria Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Malaria Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on malaria treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for malaria treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The malaria treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment: Prescription Medications; Vaccines; Diagnostic Tests; Other Treatments2) By Route of Administration: Oral; Parenteral; Intravenous
3) By Distribution Channel: Direct Tender; Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
4) By End User: Hospitals; Specialty Clinics; Homecare; Other End Users
Subsegments:
1) By Prescription Medications: Antimalarial Drugs; Prophylactic Medications2) By Vaccines: RTS,S or AS01; Other Experimental Vaccines
3) By Diagnostic Tests: Rapid Diagnostic Tests; Microscopy-Based Tests; Polymerase Chain Reaction (PCR) Tests
4) By Other Treatments: Supportive Care; Herbal Remedies; Vector Control Measures
Key Companies Mentioned: Pfizer Inc.; Merck & Co.; Johnson & Johnson; Roche Holding AG; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Merck & Co.
- Johnson & Johnson
- Roche Holding AG
- Bayer AG
- Novartis AG
- Sanofi SA
- AstraZeneca Plc
- GlaxoSmithKline PLC.
- Takeda Pharmaceutical Company Limited
- Sumitomo Chemical Co. Ltd.
- Viatris Inc.
- Eisai Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Serum Institute of India
- Cipla Ltd.
- Amneal Pharmaceuticals LLC
- Lupin Ltd.
- Zydus Lifesciences Limited
- Ipca Laboratories Ltd.
- Chongqing Holley Pharmaceutical Co. Ltd.
- Zydus Lifesciences Ltd.
- Medicines Sans Frontières
- Strides Pharma Science Limited
- Swiss Tropical and Public Health Institute (Swiss TPH)
- AdvaCare Pharma USA LLC
- Medicines for Malaria Venture (MMV)
- VLP Therapeutics LLC
- Actiza Pharmaceutical Private Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 1.62 Billion |
| Forecasted Market Value ( USD | $ 2.07 Billion |
| Compound Annual Growth Rate | 6.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
